TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from LBT Innovations Limited ( (AU:CC5) ).
In 2025, Clever Culture Systems achieved significant commercial success by securing multi-instrument orders from major pharmaceutical companies like AstraZeneca and Bristol Myers Squibb, and new contracts with Novo Nordisk and Boehringer Ingleheim. The company’s APAS® Independence technology, recognized for its unique FDA clearance, has positioned CCS as a leader in pharmaceutical microbiology automation. With a sales pipeline exceeding 150 instruments and a market valued at $2.8 billion, CCS is poised for growth amidst increasing regulatory demands and a shift towards automation in the industry. Financially, the company strengthened its position with increased revenues and shareholder confidence, reducing debt and enhancing cash reserves, setting the stage for future expansion.
More about LBT Innovations Limited
Clever Culture Systems (CCS) is a company based in Adelaide, South Australia, that provides intelligent automation solutions to microbiology laboratories. The company has developed the Automated Plate Assessment System (APAS® Independence), which uses artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates. This technology is the only US FDA-cleared AI system for automated culture plate reading and is sold to microbiology laboratories in the pharmaceutical manufacturing sector and clinical laboratories for infectious disease diagnostics.
Average Trading Volume: 1,952,823
Technical Sentiment Signal: Hold
Current Market Cap: A$65.67M
Find detailed analytics on CC5 stock on TipRanks’ Stock Analysis page.